Sanofi Adr Stock Return On Equity
| SNY Stock | USD 49.36 2.75 5.90% |
Sanofi ADR fundamentals help investors to digest information that contributes to Sanofi ADR's financial success or failures. It also enables traders to predict the movement of Sanofi Stock. The fundamental analysis module provides a way to measure Sanofi ADR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanofi ADR stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 0.07 | 0.13 |
Sanofi | Return On Equity |
Sanofi ADR Company Return On Equity Analysis
Sanofi ADR's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sanofi ADR Return On Equity | 0.0727 |
Most of Sanofi ADR's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sanofi Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Sanofi ADR is extremely important. It helps to project a fair market value of Sanofi Stock properly, considering its historical fundamentals such as Return On Equity. Since Sanofi ADR's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sanofi ADR's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sanofi ADR's interrelated accounts and indicators.
Click cells to compare fundamentals
Sanofi Return On Equity Historical Pattern
Today, most investors in Sanofi ADR Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sanofi ADR's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's return on equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sanofi ADR return on equity as a starting point in their analysis.
Sanofi ADR Return On Equity |
| Timeline |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Sanofi Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Sanofi ADR has a Return On Equity of 0.0727. This is 100.3% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 123.45% lower than that of the firm.
Sanofi Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi ADR's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi ADR could also be used in its relative valuation, which is a method of valuing Sanofi ADR by comparing valuation metrics of similar companies.Sanofi ADR is currently under evaluation in return on equity category among related companies.
Sanofi ADR Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sanofi ADR from analyzing Sanofi ADR's financial statements. These drivers represent accounts that assess Sanofi ADR's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sanofi ADR's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 112.0B | 98.7B | 110.9B | 112.5B | 101.2B | 67.8B | |
| Enterprise Value | 128.5B | 108.4B | 123.3B | 120.9B | 108.9B | 73.8B |
Sanofi Fundamentals
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 68.22 B | ||||
| Shares Outstanding | 2.5 B | ||||
| Shares Owned By Institutions | 9.95 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 2.52 X | ||||
| Revenue | 43.07 B | ||||
| Gross Profit | 31.7 B | ||||
| EBITDA | 12.96 B | ||||
| Net Income | 5.4 B | ||||
| Cash And Equivalents | 6.9 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 18.42 B | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 1.30 X | ||||
| Book Value Per Share | 59.17 X | ||||
| Cash Flow From Operations | 10.26 B | ||||
| Short Ratio | 1.71 X | ||||
| Earnings Per Share | 2.29 X | ||||
| Price To Earnings To Growth | 0.84 X | ||||
| Target Price | 59.12 | ||||
| Number Of Employees | 86.09 K | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 118.15 B | ||||
| Total Asset | 126.46 B | ||||
| Retained Earnings | 67.5 B | ||||
| Working Capital | 6.46 B | ||||
| Current Asset | 24.93 B | ||||
| Current Liabilities | 16.82 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 3.85 % | ||||
| Net Asset | 126.46 B | ||||
| Last Dividend Paid | 3.76 |
About Sanofi ADR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanofi ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi ADR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:Check out Sanofi ADR Piotroski F Score and Sanofi ADR Altman Z Score analysis. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.217 | Dividend Share 3.76 | Earnings Share 2.29 | Revenue Per Share 18.388 | Quarterly Revenue Growth 0.029 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.